Psoriasis

The VISIBLE trial demonstrated that intentional efforts to recruit and retain patients with skin of color result in a speedy enrollment process and diverse patient pool, according to a study.

Skin inflammation, such as psoriasis, was associated with systemic inflammation, whereas both psoriasis severity and systemic inflammation were linked with cardiovascular disease, according to a study.

As the year comes to a close, Healio Dermatology has assembled this year’s top psoriasis articles. 

Patients with moderate to severe psoriasis experienced higher rates of skin clearance through 1 year with oral JNJ-77242113 treatment compared with placebo, according to phase 2 study results.

New, positive topline data found icotrokinra to be effective for the treatment of moderate to severe plaque psoriasis in patients aged 12 years and older, Protagonist Therapeutics and Johnson & Johnson announced.

Roflumilast foam 0.3% improved patient-reported outcomes in scalp and body psoriasis, according to a poster presentation at the Fall Clinical Dermatology Conference.

Earlier this year, the National Psoriasis Foundation published an extensive report on the health impacts of psoriasis, including data on social stigma associated with the disease, health disparities and comorbidities.

Patients with cancer who received immune checkpoint inhibitors exhibited increased risk for psoriasis compared with those treated with chemotherapy or targeted therapy.

WASHINGTON — Dactylitis, psoriasis and other non-musculoskeletal manifestations of psoriatic arthritis can be accurately monitored through patient self-reporting, according to data presented at ACR Convergence 2024.

Around the world, approximately 125 million people suffer from psoriasis and psoriatic arthritis. On Oct. 29, World Psoriasis Day, we recognize the challenges of and treatment advances for patients with psoriasis.